DONATE

Pau Gorostiza

Group leader

Biosensors based on olfactory receptors to decipher the human sense of smell

A study led by the Institute for Bioengineering of Catalonia (IBEC) and the CIBER’s Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) describes a method that mimics the physiological response to smell.  The system makes it possible to discriminate between odours with very similar characteristics based on the binding interaction with the receptor, which causes a change in the capacitive response of the receptor. The application of this methodology opens the door to the development of highly selective olfactory biosensors.

IBEC and SJD Barcelona Children’s Hospital strengthen their collaboration with a day of translational innovation

The Institute for Bioengineering of Catalonia and the Sant Joan de Déu Barcelona Children’s Hospital have held a joint conference to strengthen collaboration in bioengineering and translational medicine. The event, held this morning at the IBEC, highlighted innovative projects, presented a joint PhD programme and encouraged the exchange of ideas between researchers from both institutions.

IBEC and VHIR hold a collaboration day to promote synergies

The 1st Translational Collaboration Day between the Vall d’Hebron Institute of Research (VHIR) and the Institute of Bioengineering of Catalonia (IBEC), held on 21st November, was an opportunity to learn about the projects and research lines of both institutions and to promote interaction between professionals.

IBEC and BST strengthen ties with Translational Collaboration Day

IBEC and the Blood and Tissue Bank of Catalonia (BST) held a day to explore new collaborations in bioengineering and translational medicine. The meeting, held yesterday at IBEC, highlighted innovative projects, presented a joint PhD programme and strengthened the link between biomedical research and clinical applications.

Light-activated drugs against neuropathic pain

A team of researchers led by the Institute for Bioengineering of Catalonia (IBEC) has developed light-activated derivatives of the anti-epileptic drug carbamazepine to treat neuropathic pain. These compounds, which show analgesic effects when activated by light, can inhibit nerve signals locally and on demand. Photopharmacological treatments offer precise action at the site of application, thus reducing systemic side effects.

Luminescent Nanoparticle-based Implants for Pain and Epilepsy Treatment

The IBEC is set to lead the coordination of the PHOTOTHERAPORT project, which will be developed with funding from the European Innovation Council’s Pathfinder Open programme. The project focuses on the development of luminescent implants and light-activated drugs for innovative neuromodulation therapies. PHOTOTHERAPORT will comprise an international consortium of 8 institutions and will receive €3 million over 3 years for the preclinical study of these implants.

Researchers induce brain activation using infrared light-controlled drugs

A pioneering study led by IBEC in collaboration with ICFO has unveiled a method to control brain activity in living organisms using drugs activated by infrared light. This cutting-edge technique activates a specific neurotransmitter receptor using light that can penetrate deep into tissue and offers unparalleled pharmacological and spatiotemporal precision in three dimensions. The findings open new frontiers for neurobiology research and the development of light-based noninvasive neuromodulation therapies.

Cookies
Cookie Consent The IBEC website uses cookies and similar technologies to ensure the basic functionality of the site and for statistical and optimisation purposes. It also uses cookies to display content such as YouTube videos that use marketing cookies. This last category consists of tracking cookies: these make it possible for your online behaviour to be tracked. You consent to this by clicking on Accept. Also read our Privacy statement. Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all